emetogenic

emetogenic

 [em″ĕ-to-jen´ik]
emetic (def. 1).

em·e·to·gen·ic

(em'ĕ-tō-jen'ik),
Having the capacity to induce emesis (vomiting), a common property of anticancer agents, narcotics, and amorphine.

em·e·to·gen·ic

(em'ĕ-tō-jen'ik)
Having the capacity to induce emesis (vomiting), a common property of some drugs.
References in periodicals archive ?
Helsinns NDA is supported by data from several clinical studies focused on the safety and pharmacokinetics of the drug in the prevention of CINV following highly emetogenic chemotherapy.
A phase II randomised double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumour patients receiving moderately to highly emetogenic chemotherapy.
The National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) have categorised chemotherapy regimens based on the degree to which they cause nausea and vomiting: low emetogenic chemotherapy (LEC), moderately emetogenic chemotherapy (MEC) and highly emetogenic chemotherapy (HEC).
The NDA filing includes data demonstrating the bioequivalence of CINVANTI to EMEND IV (fosaprepitant), supporting its efficacy for the prevention of both acute and delayed CINV with both moderately emetogenic chemotherapy (MEC) and highly emetogenic chemotherapy (HEC).
13,16,17) Cisplatin provides a model for antiemetic testing, as it is highly emetogenic and found to cause emesis in 99% of patients without antiemetics.
Akynzeo is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
Subsequent vomiting was attributed to the morphine, although nitrous oxide is also known to have potent emetogenic effects (Ho & Chiu 2005).
A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy.
Food and Drug Administration (FDA) for AKYNZEO (generic name: netupitant/palonosetron), indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including but not limited to highly emetogenic chemotherapy, in the U.
The product also can be used with initial and repeat courses of emetogenic cancer chemotherapy.
Despite the widespread use of 5-HT3 receptor antagonist anti-emetics such as Palonosetron (Aloxi; Eisai), chemotherapy induced nausea continues to be reported by 70% of adult patients and 58% of children receiving highly emetogenic chemotherapy.
4D or not 4D--the emetogenic basis of PDE4 inhibitors uncovered?